GLP-1 Treatments
Mega FAQ — April 2026

GLP-1 FAQ: 30 Questions Answered

Everything UK patients ask about GLP-1 weight loss medications — answered by evidence, not hype.

About this FAQ

  • 30 of the most commonly searched GLP-1 questions in the UK
  • All answers based on MHRA, NICE, NHS and BNF guidance
  • Updated April 2026 with the latest clinical evidence
  • Each answer links to our detailed specialist guides for further reading

The basics

1. What are GLP-1 receptor agonists?
GLP-1 receptor agonists are medications that mimic the gut hormone glucagon-like peptide-1. They reduce appetite, slow gastric emptying and improve blood sugar control. In the UK, the main options are semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). Liraglutide (Saxenda) is also available. Read our complete GLP-1 guide for a full overview.
2. What is the difference between Ozempic and Wegovy?
Both contain semaglutide manufactured by Novo Nordisk. Ozempic is licensed for type 2 diabetes at up to 2 mg weekly. Wegovy is licensed for weight management at the higher dose of 2.4 mg weekly. The active ingredient and injection mechanism are identical, but the licensed indication, dose and NHS funding pathway differ. See our full Ozempic vs Wegovy comparison.
3. How do GLP-1 medications work?
They work through multiple coordinated mechanisms: reducing appetite signals in the brain, slowing gastric emptying (so you feel full longer), improving insulin secretion, and reducing the reward value of highly palatable foods. Our guide explains how semaglutide works in detail.
4. Is Mounjaro better than Wegovy?
Mounjaro (tirzepatide) achieved greater average weight loss in trials (22.5% vs 14.9%) due to dual GLP-1 and GIP receptor action. However, individual responses vary and direct head-to-head data is limited. See our Mounjaro vs Wegovy comparison for a detailed analysis.

NHS access and cost

5. Can I get GLP-1 medication on the NHS?
Yes. NICE has approved Wegovy and Mounjaro for weight management in adults with BMI 35+ or BMI 30+ with comorbidities (adjusted lower for some ethnic groups). Access is through Tier 3 specialist weight management services. Waiting times vary regionally. See how to get Wegovy on the NHS and Mounjaro NHS access in 2026.
6. How much does GLP-1 medication cost privately?
Private monthly costs range from approximately £150–£250 for Wegovy or Mounjaro and £140–£220 for Ozempic. Prices vary between providers. See our UK vs Europe price comparison and online prescription guide.
7. Can I buy Ozempic online safely in the UK?
Yes, but only from MHRA-registered pharmacies with GPhC-registered prescribers. Counterfeit GLP-1 medications have been identified. Always verify the pharmacy on the GPhC register. Our guide to buying Ozempic online safely covers all the key safety checks.
8. Are there NHS weight loss clinics?
Yes. NHS Tier 3 specialist weight management services operate across England, Scotland, Wales and Northern Ireland. They offer multidisciplinary support including medication, dietary advice and psychological support. See our UK weight loss clinics guide and weight loss programmes.
9. When will generic Ozempic be available in the UK?
Key semaglutide patents begin expiring from 2031–2032. Biosimilar development takes several years beyond patent expiry. Generic or biosimilar options may reach the UK market in the early 2030s. See our Ozempic generic UK tracker.

Weight loss expectations

10. How much weight will I lose?
Average weight loss ranges from 15% (semaglutide 2.4 mg) to 22.5% (tirzepatide 15 mg) of body weight over 12–18 months. Individual results vary. Combining medication with dietary changes and exercise produces the best outcomes.
11. How quickly does weight loss start?
Most patients notice reduced appetite within the first 1–2 weeks. Measurable weight loss typically begins within 4–6 weeks as the dose is escalated. The rate of loss accelerates over the first 6 months before gradually plateauing around month 12–15.
12. Will I regain weight if I stop the medication?
Weight regain is common. Studies show approximately two-thirds of lost weight returns within 12 months of stopping. This is why long-term treatment is recommended and stopping requires careful planning with lifestyle reinforcement.
13. How long do I need to take GLP-1 medication?
Current guidance supports long-term use for chronic weight management, similar to medications for hypertension or diabetes. Annual reviews with your prescriber assess ongoing benefit. Some patients may be able to reduce to a lower maintenance dose.

Side effects and safety

14. What are the most common side effects?
Gastrointestinal symptoms dominate: nausea (30–44%), vomiting (10–15%), diarrhoea (15–25%) and constipation (10–20%). These typically improve within 4–8 weeks. See our comprehensive GLP-1 side effects guide and Ozempic-specific side effects.
15. Will I lose my hair?
Some patients experience temporary hair shedding (telogen effluvium) from rapid weight loss. It is not a direct drug effect. Hair typically regrows within 6–12 months. Adequate protein, iron and biotin help. See Ozempic and hair loss.
16. What about "Ozempic face"?
Facial volume loss (hollowed cheeks, sagging) can occur with significant weight loss from any cause. Prevention includes gradual weight loss, protein intake and sun protection. Treatment options exist if it occurs. See our full guide on Ozempic face explained.
17. Can I drink alcohol on GLP-1 medication?
Alcohol is not contraindicated but should be consumed cautiously. GLP-1 RAs may increase alcohol sensitivity and worsen nausea. Alcohol also adds empty calories. Stay within NHS guidelines of 14 units per week. See Ozempic and alcohol.
18. Do GLP-1 medications cause cancer?
Current evidence does not confirm increased cancer risk in humans. A precautionary thyroid warning exists from rodent studies. GLP-1 RAs are contraindicated in medullary thyroid carcinoma/MEN2. See GLP-1 and cancer risk and thyroid concerns.
19. Will GLP-1 medication cause muscle loss?
Any weight loss involves some lean mass reduction (typically 25–40% of weight lost). This can be significantly mitigated with adequate protein intake (1.2–1.6 g/kg/day) and resistance training. See preventing muscle loss on GLP-1.

Practical questions

20. How do I inject the medication?
GLP-1 RAs use pre-filled pens for subcutaneous injection into the abdomen, thigh or upper arm. Rotate sites weekly. The injection takes seconds and uses a very fine needle. See our step-by-step injection guide.
21. Is there an oral option instead of injections?
Yes. Oral semaglutide (Rybelsus) is available for type 2 diabetes. Higher-dose oral formulations for weight management are in development. You can also compare weekly vs daily injection options.
22. What diet should I follow?
Prioritise protein-rich foods, vegetables, fruits and wholegrains. Eat smaller, more frequent meals. Avoid greasy and spicy foods, especially early in treatment. Stay hydrated. See our full diet on GLP-1 medication guide.
23. Should I exercise?
Absolutely. Aim for 150 minutes of moderate activity weekly plus resistance training twice weekly. Exercise preserves muscle, improves cardiovascular fitness and enhances medication efficacy. See exercise on GLP-1 medication.
24. What if I miss a dose?
If more than 2 days remain until your next dose, take the missed dose immediately. If fewer than 2 days, skip it and resume your normal schedule. Never double dose. If you miss 2+ consecutive doses, your prescriber may advise restarting at a lower dose.

Special situations

25. Can I take GLP-1 medication during pregnancy?
No. GLP-1 RAs are contraindicated in pregnancy and breastfeeding. Stop at least 2 months before planned conception. If you discover you are pregnant, stop immediately and contact your prescriber. See pregnancy and GLP-1.
26. Do GLP-1 drugs affect fertility?
Weight loss may improve fertility in women with PCOS and obesity-related anovulation. However, medications must be stopped before conception. Improved ovulation during treatment can lead to unexpected pregnancy — use contraception. See GLP-1 and fertility.
27. Are GLP-1 medications safe for over-65s?
They can be prescribed but require careful monitoring for muscle loss, falls risk and nutritional adequacy. Protein and resistance exercise are essential. Dose escalation may be slower. See GLP-1 for over 65s.
28. Can teenagers use Wegovy?
Wegovy is licensed for adolescents aged 12+ with obesity, under specialist paediatric supervision. Growth, development and psychological impact must be monitored. Mounjaro is not yet licensed for under-18s in the UK.

Beyond weight loss

29. Do GLP-1 medications reduce heart attack risk?
Yes. The SELECT trial demonstrated a 20% reduction in major cardiovascular events with semaglutide 2.4 mg. NICE has approved Wegovy for cardiovascular risk reduction. GLP-1 RAs also improve cholesterol and reduce inflammation. See GLP-1 and heart health.
30. What other health benefits do GLP-1 medications have?
Beyond weight loss and diabetes control, evidence supports benefits for fatty liver disease, kidney protection, sleep apnoea, joint health, prediabetes prevention and gut health. New indications are being actively researched. See future treatments and our obesity treatment overview.

Explore all our specialist guides

Sources